A Comparative Study of the Efficacy of Methotrexate versus Methotrexate with Apremilast in Moderate to Severe Chronic Plaque Psoriasis
Background: Psoriasis is an inflammatory systemic disease with a chronic relapsing course. Methotrexate, a dihydrofolate reductase inhibitor, and Apremilast, an oral phosphodiesterase type 4 inhibitor, are currently the mainstay drugs in the treatment of psoriasis. Aims and Objectives: To compare th...
Main Authors: | Divyanshu Srivastava, Arvind Krishna, Abhinav David |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2023-01-01
|
Series: | Indian Journal of Dermatology |
Subjects: | |
Online Access: | http://www.e-ijd.org/article.asp?issn=0019-5154;year=2023;volume=68;issue=4;spage=393;epage=398;aulast=Srivastava |
Similar Items
-
Real-world efficacy and safety of apremilast monotherapy in the management of moderate-to-severe Psoriasis
by: Bela J Shah, et al.
Published: (2020-01-01) -
The Effect of Methotrexate 1% Topical Gel on Psoriasis
by: Gita Faghihi, et al.
Published: (2012-03-01) -
Erythrodermic psoriasis treated with apremilast
by: John Arcilla, et al.
Published: (2016-09-01) -
Experience in the treatment of psoriasis patients using Apremilast, a selective signalling pathway inhibitor
by: N. V. Kungurov, et al.
Published: (2019-04-01) -
Efficacy of Leflunomide Compared to Methotrexate in the Treatment of Moderate to Severe Plaques Psoriasis: A Randomized Controlled Clinical Trial
by: Hany Aboelwafa, et al.
Published: (2024-07-01)